Compare JQC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | OLMA |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 725.5M |
| IPO Year | N/A | 2020 |
| Metric | JQC | OLMA |
|---|---|---|
| Price | $5.01 | $35.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $40.50 |
| AVG Volume (30 Days) | 714.6K | ★ 8.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.82 | $2.86 |
| 52 Week High | $5.65 | $33.50 |
| Indicator | JQC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 85.25 |
| Support Level | $5.00 | $25.62 |
| Resistance Level | $5.08 | $33.50 |
| Average True Range (ATR) | 0.04 | 2.33 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 25.00 | 95.78 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.